News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Passage Bio has exercised two additional options for potential new drug candidates under its research collaboration with Penn's gene therapy program.
Strategic partnership combines the start-ups’ revolutionary technologies for brain injury reduction and cognitive performance
In experiments using saliva samples from COVID-19 patients, the gum, which contains the ACE2 protein, neutralized the virus, according to research led by School of Dental Medicine scientists.
The event honors the patent recipients from the previous fiscal year, as well as, those partners, inventors, and startups that made exceptional achievements.
The Penn Center for Innovation had the most-ever patents issued for Penn and its affiliates this year, according to the center's 2021 Year in Review.
A chewing gum impregnated with a plant-grown protein can serve as a “trap” for the SARS-CoV-2 virus, reducing viral load in the chewers saliva and potentially tamping down transmission.
With its highest number of patents issued, commercial agreements, corporate-sponsored research funding, and licensing revenue receipts in a single period, PCI experienced a landmark fiscal year.
Carter Caldwell, the Director of the Penn Medicine Co-Investment Program, wrote a guest blog for Penn Medicine News on how the University has impacted his life as a student, a patient, and an employee
Unique to both Penn and across higher education, the Prize underscores the University’s considerable commitment to encouraging students to put their knowledge to work for the betterment of humankind.
The Penn Biotech Healthcare Consulting Group has a podcast called "Science to Suits" focused on healthcare and biotech commercialization.